LncRNA MIR22HG and miR-10a-5p: Pioneering serum biomarkers for pancreatic cancer diagnosis and progression assessment
Rowyda M Salman, Abdullah F Radwan, Olfat G Shaker, Ahmed A El-Husseiny · 2026
Read LncRNA MIR22HG and miR-10a-5p: Pioneering serum biomarkers for pancreatic cancer diagnosis and progression assessment by Rowyda M Salman, Abdullah F Radwan, Olfat G Shaker, Ahmed A El-Husseiny (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13259623.txt.
Description
Rowyda Salman and co-authors hunt pancreatic cancer in a blood draw. The disease is usually found too late, so circulating RNA signals that betray it early are prized. Their 2026 case-control study compares sixty-five patients with twenty-five healthy volunteers.
Two RNAs moved in opposite directions in patients: the long RNA MIR22HG fell, while a small RNA named miR-10a-5p rose. Each alone separated patients from controls with striking accuracy, and adding them sharpened the classic blood markers. Low MIR22HG also tracked with cancer that had already spread. The pair could anchor earlier diagnosis and better staging, the authors argue.
Catalog record
| CREATOR | Rowyda M Salman, Abdullah F Radwan, Olfat G Shaker, Ahmed A El-Husseiny |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |